Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy

Targeted therapy and hand–foot skin reaction in advanced renal cell carcinoma

(2010) Chih-Hsun Yang et al.   Expert Opinion On Drug Safety

Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma

(2010) Y. Tomita et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction

(2010) C. Yoo et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

(2009) B. E. Houk et al.   CLINICAL CANCER RESEARCH

A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety

(2009) H. Uemura et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity

(2009) Nielka P. van Erp et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

(2009) Martin E Gore et al.   LANCET ONCOLOGY

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY